(R)-Ofloxacin | antibiotic | CAS#100986-86-5

MedKoo Cat#: 333018 | Name: (R)-Ofloxacin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(R)-Ofloxacin is a R-isomer of Ofloxacin, which is an antibiotic useful for the treatment of a number of bacterial infections.

Chemical Structure

(R)-Ofloxacin

CAS#100986-86-5

Theoretical Analysis

MedKoo Cat#: 333018

Name: (R)-Ofloxacin

CAS#: 100986-86-5

Chemical Formula: C18H20FN3O4

Exact Mass: 361.1438

Molecular Weight: 361.37

Elemental Analysis: C, 59.83; H, 5.58; F, 5.26; N, 11.63; O, 17.71

Price and Availability

Size	Price	Availability
25mg	USD 150.00	Ready to ship
50mg	USD 250.00	Ready to ship
100mg	USD 450.00	Ready to ship
200mg	USD 850.00	Ready to ship
500mg	USD 1,650.00	Ready to ship
1g	USD 2,950.00	Ready to ship
2g	USD 4,950.00	Ready to ship
5g	USD 7,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

100986-86-5 82419-36-1

Synonym

(R)-Ofloxacin, (+)-Ofloxacin; (R)-(+)-Ofloxacin; D-Ofloxacin; DR 3354; DR-3354; DR3354; d-Levofloxacin; Dextrofloxacin;

IUPAC/Chemical Name

(3R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid

InChi Key

GSDSWSVVBLHKDQ-SNVBAGLBSA-N

InChi Code

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m1/s1

SMILES Code

O=C(C(C1=O)=CN2[C@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#T9D11P09

View CoA: current batch, Lot#T9D12P04

QC Data

View QC data: current batch, Lot#T9D11P09

View QC data: current batch, Lot#T9D12P04

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	55.34
	DMSO	20.0	55.34
	Ethanol	1.0	2.77
	PBS (pH 7.2)	10.0	27.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 361.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Abousalih FZ, Karbane ME, Echerfaoui F, Benchekroun YH, Karrouchi K, Azougagh M, Bouchafra H, Bouatia M. Optimization of a Ligand Exchange Chromatography Method for the Enantioselective Separation of Levofloxacin and Its Chiral Impurity. J AOAC Int. 2021 Dec 11;104(6):1690-1697. doi: 10.1093/jaoacint/qsab077. PMID: 34115099. 2: Castrignanò E, Yang Z, Feil EJ, Bade R, Castiglioni S, Causanilles A, Gracia- Lor E, Hernandez F, Plósz BG, Ramin P, Rousis NI, Ryu Y, Thomas KV, de Voogt P, Zuccato E, Kasprzyk-Hordern B. Enantiomeric profiling of quinolones and quinolones resistance gene qnrS in European wastewaters. Water Res. 2020 May 15;175:115653. doi: 10.1016/j.watres.2020.115653. Epub 2020 Mar 10. Erratum in: Water Res. 2020 Sep 1;182:116345. doi: 10.1016/j.watres.2020.116345. PMID: 32208173. 3: Urbaniak B, Milanowski B, Lulek J, Kokot ZJ. STUDY OF OFLOXACIN ENANTIOMERS DISSOLUTION FROM SELECTED SOLID DOSAGE FORMS USING HIGH PERFORMANCE CAPILLARY ELECTROPHORESIS METHOD. Acta Pol Pharm. 2017 May;74(3):955-968. PMID: 29513966. 4: Nie J, Wang YG, Gao XF, OuYang XK, Yang LY, Yu D, Wu WJ, Xu HP. Pharmacokinetic study of ofloxacin enantiomers in Pagrosomus major by chiral HPLC. Biomed Chromatogr. 2016 Mar;30(3):426-31. doi: 10.1002/bmc.3565. Epub 2015 Aug 27. PMID: 26179954. 5: Mu H, Lei H, Wang B, Xu Z, Zhang C, Ling L, Tian Y, Hu J, Sun Y. Molecular modeling application on hapten epitope prediction: an enantioselective immunoassay for ofloxacin optical isomers. J Agric Food Chem. 2014 Aug 6;62(31):7804-12. doi: 10.1021/jf404449n. Epub 2014 Jul 29. PMID: 25069865. 6: Fang Z, Guo Z, Qin Q, Fan J, Yin Y, Zhang W. Semi-preparative enantiomeric separation of ofloxacin by HPLC. J Chromatogr Sci. 2013 Feb;51(2):133-7. doi: 10.1093/chromsci/bms117. Epub 2012 Jul 19. PMID: 22815212. 7: Lee HM, Kim HD, Kim JM, Kim JK, Kim SK. Molecular modeling study on the enantioselective binding of S- and R-ofloxacin to various DNA sequences. J Biomol Struct Dyn. 2007 Dec;25(3):231-42. doi: 10.1080/07391102.2007.10507172. PMID: 17937485. 8: Gong QJ, Jin WJ, Dong C. [Transformation of S- (+)-ofloxacin enantiomer in human body and determination by synchronous-derivative fluorimetry]. Guang Pu Xue Yu Guang Pu Fen Xi. 2001 Oct;21(5):688-90. Chinese. PMID: 12945333. 9: Awadallah B, Schmidt PC, Wahl MA. Quantitation of the enantiomers of ofloxacin by capillary electrophoresis in the parts per billion concentration range for in vitro drug absorption studies. J Chromatogr A. 2003 Feb 21;988(1):135-43. doi: 10.1016/s0021-9673(02)02015-0. PMID: 12647828. 10: Hwangbo HJ, Yun BH, Cha JS, Kwon DY, Kim SK. Enantioselective binding of S- and R-ofloxacin to various synthetic polynucleotides. Eur J Pharm Sci. 2003 Feb;18(2):197-203. doi: 10.1016/s0928-0987(02)00279-8. PMID: 12594014. 11: Lee EJ, Yeo JA, Jung K, Hwangbo HJ, Lee GJ, Kim SK. Enantioselective binding of ofloxacin to B form DNA. Arch Biochem Biophys. 2001 Nov 1;395(1):21-4. doi: 10.1006/abbi.2001.2563. PMID: 11673861. 12: Gascón AR, Campo E, Hernández RM, Calvo B, Errasti J, Pedraz Muñoz JL. Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. J Clin Pharmacol. 2000 Aug;40(8):869-74. doi: 10.1177/00912700022009602. PMID: 10934671. 13: Zeng S, Zhong J, Pan L, Li Y. High-performance liquid chromatography separation and quantitation of ofloxacin enantiomers in rat microsomes. J Chromatogr B Biomed Sci Appl. 1999 May 14;728(1):151-5. doi: 10.1016/s0378-4347(99)00085-7. PMID: 10379667. 14: Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. Absorption of ofloxacin isomers in the rat small intestine. Antimicrob Agents Chemother. 1997 Oct;41(10):2274-7. doi: 10.1128/AAC.41.10.2274. PMID: 9333061; PMCID: PMC164106. 15: Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997 Feb;32(2):101-19. doi: 10.2165/00003088-199732020-00002. PMID: 9068926. 16: Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob Agents Chemother. 1996 Sep;40(9):2126-30. doi: 10.1128/AAC.40.9.2126. PMID: 8878593; PMCID: PMC163485. 17: Morrissey I, Hoshino K, Sato K, Yoshida A, Hayakawa I, Bures MG, Shen LL. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother. 1996 Aug;40(8):1775-84. doi: 10.1128/AAC.40.8.1775. PMID: 8843280; PMCID: PMC163416. 18: Zeng S, Zhang L, Liu ZQ. [Quantification of the enantiomers of ofloxacin in human urine by RP-HPLC with chiral mobile phase additive]. Yao Xue Xue Bao. 1994;29(3):223-7. Chinese. PMID: 8079649. 19: Tanaka M, Otsuki M, Une T, Nishino T. In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. J Antimicrob Chemother. 1990 Nov;26(5):659-66. doi: 10.1093/jac/26.5.659. PMID: 2079448.